Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Наблюдательное исследование, позволяющее узнать больше о безопасности даролутамида у мужчин с раком простаты в Корее

4 ноября 2026 г. обновлено: Bayer

Постмаркетинговое исследование по изучению одобренного применения даролутамида у корейских пациентов

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.

This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.

To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.

Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

Обзор исследования

Тип исследования

Наблюдательный

Регистрация (Оцененный)

600

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

19 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Мужской

Метод выборки

Невероятностная выборка

Исследуемая популяция

Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.

Описание

Inclusion Criteria:

  • Male aged ≥19 years

  • Patients with high risk nmCPRC

    • Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
    • PSA doubling time < 10 months
  • Patients with mHSPC

    • histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
    • be candidates for androgen-deprivation therapy with/without docetaxel.
  • Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice

  • Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Participants with contraindication according to the locally approved prescribing information

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Наблюдательные модели: COHORT
  • Временные перспективы: PROSPECTIVE

Когорты и вмешательства

Группа / когорта
Вмешательство/лечение
Male patients with nmCRPC or mHSPC

Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number, severity of adverse events (including SAEs)
Временное ограничение: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
Временное ограничение: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
Временное ограничение: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
Временное ограничение: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Причины прекращения приема даролутамида
Временное ограничение: До 52 недель
До 52 недель
Дозировка и модификация дозы даролутамида
Временное ограничение: До 52 недель
До 52 недель
Metastasis-free survival (MFS) by nmCRPC indication
Временное ограничение: Up to 52 weeks

MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Временное ограничение: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Временное ограничение: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by nmCRPC indication
Временное ограничение: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Временное ограничение: Up to 52 weeks

Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Временное ограничение: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Временное ограничение: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by mHSPC indication
Временное ограничение: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Временное ограничение: Up to 52 weeks

Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.

Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Временное ограничение: Up to 52 weeks

Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Временное ограничение: Up to 52 weeks

Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.

Up to 52 weeks
Duration of Darolutamide treatment
Временное ограничение: Up to 52 weeks

Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).

Up to 52 weeks

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

25 сентября 2024 г.

Первичное завершение (Оцененный)

31 марта 2028 г.

Завершение исследования (Оцененный)

30 июня 2028 г.

Даты регистрации исследования

Первый отправленный

21 марта 2024 г.

Впервые представлено, что соответствует критериям контроля качества

21 марта 2024 г.

Первый опубликованный (Действительный)

27 марта 2024 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

4 ноября 2026 г.

Последняя проверка

4 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 20654

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Описание плана IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться